调查显示:民众对北京市“医药分开”综合改革满意度近70%

2017-08-04 马海燕 中国新闻网

2017年6月起开展的针对北京市“医药分开”改革认知与感受的电话调查,近日调查结果出炉,满意度近70%。


记者3日从中国人民大学获悉,该校统计学院多名老师参与的一项“中国医疗消费和养老状况评价跟踪调查”显示,民众对北京市“医药分开”综合改革的满意度达69.8%。

北京市自今年4月8日起全面推行“医药分开”综合改革,参与改革的3600多所医疗机构,都取消了挂号费、诊疗费、药品加成,设立医事服务费,435项医疗服务价格也进一步规范调整。

调查显示,75.9%的受访者认为此次改革对未来看病有积极影响或没有影响,55.3%的人认为改革后医事服务费偏高,认为药品价格偏高的人占27.6%。

将最近一次看病费用与改革前相比,有51.2%的人认为自行支付的总费用基本不变,也有37.4%的人认为自付总费用有所上升,10.4%的人认为有所下降。

把药品费用和检查费用分开看,有55.1%的人认为自付的药品费用基本不变,有18.1%的人认为自付药品费有所上升,26.8%的人认为有所下降。

本次调查也发现,对此次改革满意度较低的人群更多集中在低学历和就医医院级别较高等特征人群中;认为改革后自付的医事服务费与药费偏高的更多集中在低收入家庭;认为改革新政对未来看病有消极影响的更多集中在高年龄和低收入人群中。

报告建议,北京市“医药分开”改革应进一步关注低收入、高年龄、无业等较为弱势的群体,一方面通过宣传教育提高他们对改革的认知水平,另一方面,通过政策调整,为他们病有所医提供保障。

本次调查由中国人民大学客座教授、美国耶鲁大学公共卫生学院教授马双鸽发起,中国人民大学统计学院副院长王晓军牵头。项目组采用电话调查方式,随机抽样,于今年6月起开展,有效样本共632个。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944856, encodeId=d6a31944856ba, content=<a href='/topic/show?id=b880e913326' target=_blank style='color:#2F92EE;'>#综合改革#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79133, encryptionId=b880e913326, topicName=综合改革)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Oct 04 18:55:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409017, encodeId=d449140901ea6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478651, encodeId=331b14e86510b, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534914, encodeId=67161534914e4, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230018, encodeId=2ee82300187a, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Aug 04 18:16:27 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944856, encodeId=d6a31944856ba, content=<a href='/topic/show?id=b880e913326' target=_blank style='color:#2F92EE;'>#综合改革#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79133, encryptionId=b880e913326, topicName=综合改革)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Oct 04 18:55:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409017, encodeId=d449140901ea6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478651, encodeId=331b14e86510b, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534914, encodeId=67161534914e4, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230018, encodeId=2ee82300187a, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Aug 04 18:16:27 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
    2017-08-06 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944856, encodeId=d6a31944856ba, content=<a href='/topic/show?id=b880e913326' target=_blank style='color:#2F92EE;'>#综合改革#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79133, encryptionId=b880e913326, topicName=综合改革)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Oct 04 18:55:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409017, encodeId=d449140901ea6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478651, encodeId=331b14e86510b, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534914, encodeId=67161534914e4, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230018, encodeId=2ee82300187a, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Aug 04 18:16:27 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944856, encodeId=d6a31944856ba, content=<a href='/topic/show?id=b880e913326' target=_blank style='color:#2F92EE;'>#综合改革#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79133, encryptionId=b880e913326, topicName=综合改革)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Oct 04 18:55:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409017, encodeId=d449140901ea6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478651, encodeId=331b14e86510b, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534914, encodeId=67161534914e4, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230018, encodeId=2ee82300187a, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Aug 04 18:16:27 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1944856, encodeId=d6a31944856ba, content=<a href='/topic/show?id=b880e913326' target=_blank style='color:#2F92EE;'>#综合改革#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79133, encryptionId=b880e913326, topicName=综合改革)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Oct 04 18:55:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409017, encodeId=d449140901ea6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478651, encodeId=331b14e86510b, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534914, encodeId=67161534914e4, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Sun Aug 06 08:55:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230018, encodeId=2ee82300187a, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Fri Aug 04 18:16:27 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
    2017-08-04 1e0e5697m83(暂无匿称)

    henhao

    0

相关资讯

JAMA Surgery:自体脂肪用于乳房重建满意度更高

根据《JAMA Surgery》发表的一项研究显示,使用脂肪移植术作为乳房切除术后乳房重建的工具,或可改善乳房满意度、心理健康和性幸福感。

ASES 2016:反向肩关节置换术,负重或不负重患者的效果类似

根据发表在美国肩肘外科年会的研究结果,负重组患者的反向肩关节置换术后的效果和满意度,与非承重组患者相似。“负重的患者与非承重组有类似的结果和满意度!”Derek J. Cuff博士,在他的演讲中说。Cuff和同事们对进行反向肩关节置换术的患者分组,分为负重组(n=21)或非负重组(n=72)。研究人员比较了两组患者的美国肩肘外科医师学会(ASES)评分、肩测试评分、运动相关测量、放射学检查结果及患

2017中国更佳医学院校毕业生满意度排行榜出炉,上医、协和、湘雅校友最自豪!

昨天《医学界》发布了2017中国最佳医学院校综合排行榜(点击蓝字可查看),引起业内广泛反响,今天,《医学界》基于教学与课程、学校设施、实习与就业、校园文化及服务和总体评价等方面发起调研,推出《2017中国最佳医学院校毕业生满意度排行榜》,一起来看看吧!

J Arthroplasty:初次关节置换术后患者满意度的影响因素

髋、膝关节置换术是目前临床上最为成功的替代物置入手术,可以从很大程度上改善患者的疼痛和功能障碍。但是,随着置换关节使用年限的增加,假体松动,感染等事件概率发生呈现逐步上升趋势,患者满意度呈现下降趋势。 目前临床上尚缺乏对短期(2-5年)内关节置换术后满意度相关因素的研究,Lexington等人对此题目进行研究,结论发表于JOA杂志上。 研究者共收集1009例初次膝关节置换术的患者数据,包括膝关

Eur Spine J:患者的手术治疗决策权与术后满意度无关

提高患者的自主决策权被认为是改进医疗服务的重要一环。患者对治疗措施的决策权,依赖于当今医生为患者提供的信息越来越多。随着医患关系和共享决策权模式的发展,患者开始愿意积极参与他们的治疗措施的决策。然而,并非所有的患者都对自己成为治疗措施的决策者感到满意,或者想成为一名决策者。一些研究人员曾报道,参与程度本身(被动的,协同的,主动的)甚至会对实际决策产生负面影响。 以患者为中心的决策,会达成

JOT:如何提高骨科创伤患者满意度

患者的满意度,是衡量我们医疗质量优劣的重要因素。2007年以来,我国在医疗卫生行业中试点开展“两好一满意”活动,活动率先在山东开展,取得满意效果。这“一满意”,就是患者满意。由于我们面对的患者来自各个行业,性格各异,能让每个患者满意,确非易事。如何真正提高患者的满意度,是值得我们每一个医护人员思考的问题。【原文下载】 近来,美国学者Morris等进行了一项相关研究,值得我们学习借鉴。调查发现